

Appl. No. 10/076,071
Amdt. dated December 24, 2008
Reply to Office Action mailed October 2, 2008

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-530 (Canceled).

531. (Previously presented) A method of treating an angiogenic disease or condition in an animal comprising administering to the animal an amount of a metal-binding peptide which does not have a metal ion bound to it or of a physiologically-acceptable salt of the peptide, the amount of the peptide or salt which is administered to the animal being effective to inhibit angiogenesis, the sequence of the peptide being:

$P_1 - P_2$,

wherein:

P_1 is:

$Xaa_1 Xaa_2 His$ or

$Xaa_1 Xaa_2 His Xaa_3$,

the P_1 portion of the peptide being linear;

Xaa_1 is the N-terminal amino acid of the peptide, the only substituents on the α -amino group of Xaa_1 are hydrogen, and Xaa_1 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or α -hydroxymethylserine;

Xaa_2 is alanine, β -alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or α -hydroxymethylserine;

Xaa_3 is glycine, alanine, valine, lysine, arginine, ornithine, aspartic acid, glutamic acid, asparagine, glutamine or tryptophan; and

P_2 is an amino acid sequence which comprises the sequence of a Cu(I) binding site, and P_2 contains no more than 10 amino acids.

Appl. No. 10/076,071
Amdt. dated December 24, 2008
Reply to Office Action mailed October 2, 2008

532. (Previously presented) The method of Claim 531 wherein:

Xaa₁ is glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, glutamic acid, lysine, hydroxylysine, histidine, arginine, or α -hydroxymethylserine, and

Xaa₂ is alanine, valine, leucine, isoleucine, threonine, serine, asparagine, glutamine, cysteine, methionine, lysine, hydroxylysine, histidine, arginine, or α -hydroxymethylserine.

533. (Previously presented) The method of Claim 531 wherein Xaa₁ is aspartic acid, glutamic acid, arginine, threonine or α -hydroxymethylserine.

534. (Previously presented) The method of Claim 531 wherein Xaa₂ is alanine, valine, leucine, isoleucine, threonine, serine, asparagine, methionine, histidine or α -hydroxymethylserine.

535. (Previously presented) The method of Claim 531 wherein Xaa₃ is lysine.

536. (Previously presented) The method of Claim 531 wherein:

Xaa₁ is aspartic acid, glutamic acid, arginine, lysine, threonine, serine or α -hydroxymethylserine,

Xaa₂ is alanine, valine, leucine, isoleucine, threonine, serine, asparagine, methionine, histidine or α -hydroxymethylserine, and

Xaa₃, when present, is lysine.

537. (Previously presented) The method of Claim 536 wherein Xaa₁ is aspartic acid or glutamic acid and Xaa₂ is alanine, valine, leucine, isoleucine, threonine, serine or α -hydroxymethylserine.

538. (Previously presented) The method of Claim 537 wherein Xaa₂ is alanine, valine, leucine or isoleucine.

539. (Previously presented) The method of Claim 538 wherein P₁ is Asp Ala His or Asp Ala His Lys.

540. (Previously presented) The method of Claim 539 wherein P₁ is Asp Ala His Lys.

541. (Previously presented) The method of Claim 536 wherein Xaa₁ is arginine, lysine, threonine, serine or α -hydroxymethylserine, and Xaa₂ is alanine, valine, leucine, isoleucine, threonine, serine or α -hydroxymethylserine.

542. (Previously presented) The method of Claim 541 wherein P₁ is Thr Leu His, HMS HMS His or Arg Thr His.

Appl. No. 10/076,071
Amdt. dated December 24, 2008
Reply to Office Action mailed October 2, 2008

543-550 (Canceled)

551. (Currently amended) The method of Claim 531 wherein P₂ comprises one of the following sequences:

Met Xaa₄ Met,
Met Xaa₄ Xaa₄ Met,
Cys Cys,
Cys Xaa₄ Cys,
Cys Xaa₄ Xaa₄ Cys,
Met Xaa₄ Cys Xaa₄ Xaa₄ Cys,
Gly Met Xaa₄ Cys Xaa₄ Xaa₄ Cys [SEQ ID NO:7],
Gly Met Thr Cys Xaa₄ Xaa₄ Cys [SEQ ID NO:8],
Gly Met Thr Cys Ala Asn Cys [SEQ ID NO:9], or
γ-Glu Cys Gly;

wherein Xaa₄ is any amino acid.

552. (Previously presented) The method of Claim 551 wherein P₂ is Gly Met Thr Cys Ala Asn Cys [SEQ ID NO:9].

553-554. (Canceled)

555. (Previously presented) The method of Claim 531 wherein at least one of the amino acids of P₁ other than β-alanine or glycine, when present, is a D-amino acid.

556-557 (Canceled)

558. (Previously presented) The method of Claim 531 or 555 wherein at least one of the amino acids of P₂ other than β-alanine or glycine, when present, is a D-amino acid.

559. (Canceled)

560. (Previously presented) The method of Claim 531 wherein the terminal -COOH of P₁-P₂ is substituted to produce -COR₂, wherein R₂ is -NH₂, -NHR₁, -N(R₁)₂, -OR₁, or -R₁, wherein R₁ is an alkyl, aryl or heteroaryl.

561-568. (Canceled)

569. (Previously presented) The method of Claim 531 wherein the angiogenic disease or condition is a neoplastic disease, a connective tissue disorder, psoriasis, an ocular angiogenic

Appl. No. 10/076,071
Amdt. dated December 24, 2008
Reply to Office Action mailed October 2, 2008

disease, a cardiovascular disease, a cerebral vascular disease, hemophiliac joints, an immune disorder, a benign tumor, hypertrophy, endometriosis, polyposis, or obesity.

570. (Previously presented) The method of Claim 569 wherein the angiogenic disease or condition is a neoplastic disease.

571. (Previously presented) The method of Claim 570 wherein the neoplastic disease is a tumor.

572. (Previously presented) The method of Claim 571 wherein the tumor is located in the bladder, brain, breast, kidney, liver, pancreas, lung, cervix, ovary, prostate, stomach, intestines, colon, rectum, or uterus.

573. (Previously presented) The method of Claim 570 wherein the neoplastic disease is tumor metastasis.

574. (Previously presented) The method of Claim 569 wherein the angiogenic disease or condition is psoriasis.

575. (Previously presented) The method of Claim 569 wherein the angiogenic disease or condition is an ocular angiogenic disease.

576. (Previously presented) The method of Claim 575 wherein the ocular angiogenic disease is macular degeneration.

577-580. (Canceled)

581. (Previously presented) The method of Claim 551 wherein P₁ is Asp Ala His or Asp Ala His Lys.

582. (Previously presented) The method of Claim 552 wherein P₁ is Asp Ala His or Asp Ala His Lys.